Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect (D-MNA) to treat basal cell …
Medicus Pharma Submits Orphan Drug Application for SkinJect Read More
WASHINGTON, D.C. — President Donald J. Trump has signed an executive order directing federal agencies to accelerate research, regulatory review, and potential patient access for experimental psychedelic drugs aimed at …
Trump Order Expands Federal Push on Psychedelic Therapies Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate imdusiran for the treatment of …
Arbutus Drug Candidate Receives FDA Fast Track Designation Read More
WASHINGTON, D.C. — Federal regulators are exploring whether testosterone replacement therapy could be expanded to treat low libido in certain men, a move that could broaden access to treatment for …
FDA Signals Potential Expansion of Testosterone Therapy Use Read More
WASHINGTON, D.C. — Federal regulators are advancing new safety standards for gene-editing therapies, aiming to speed development of treatments for rare and previously incurable diseases while tightening oversight of potential …
FDA Moves to Fast-Track Gene Editing Safety Standards Read More
WASHINGTON, D.C. — Federal regulators are pushing thousands of companies and researchers to disclose missing clinical trial results, warning that gaps in reporting may distort how drugs and medical products …
FDA Presses Firms to Report Missing Clinical Trial Results Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More
WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) recently received preliminary feedback from the U.S. Food and Drug Administration on labeling for its preservative-free ketamine product, as the company continues …
NRx Receives FDA Feedback on Ketamine Drug Labeling Read More
PHILADELPHIA, PA — The U.S. Food and Drug Administration recently granted Breakthrough Therapy Designation to plixorafenib, an investigational drug from FORE Biotherapeutics, for the treatment of adults with BRAF V600E-mutated …
FDA Grants Breakthrough Status to Fore Bio Brain Cancer Drug Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it has submitted an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration for teverelix, an investigational …
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA Read More